BRIEF-Ziopharm Oncology Says Effective Dec 28, 2021 Co, As Borrower, Entered First Amendment To Loan, Security Agreement, Dated August 6, 2021

Reuters
05 Jan 2022

Jan 4 (Reuters) - ZIOPHARM Oncology Inc :

* ZIOPHARM ONCOLOGY - EFFECTIVE DEC 28, 2021, CO, AS BORROWER, ENTERED FIRST AMENDMENT TO LOAN, SECURITY AGREEMENT, DATED AUGUST 6, 2021

* ZIOPHARM ONCOLOGY - AMENDED AGREEMENT EXTENDS INTEREST-ONLY PERIOD THROUGH AUGUST 31, 2022

* ZIOPHARM - AMENDMENT PROVIDES FOR EXTENSION OF INTEREST-ONLY PERIOD THROUGH AUG 31, 2023, IF, ON/PRIOR TO AUG 31, 2022 CO MEETS AMENDED MILESTONES

* ZIOPHARM ONCOLOGY - AMENDMENT REMOVES TERM B TRANCHE, WHICH REMAINED UNFUNDED, LEAVING ONLY TERM A TRANCHE

* ZIOPHARM -AMENDMENT PROVIDES TERM LOAN WILL MATURE ON AUG 1, 2023; PROVIDED, CO ACHIEVES MILESTONES ON/PRIOR TO AUG 31, 2022 FOR EXTENTION OF MATURITY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10